On October 19, 2017, Eirgenix held the whole New "Protein Drug Commercial Production Plant" beam-raising ceremony at Zhubei Bio-Medical Park in Hsinchu. The first stage of this Zhubei plant is scheduled to be completed by the end of 2018 and it is going to begin formal operation in the fourth quarter in the same year.

Eirgenix is one of the largest in Taiwan's biopharmaceutical industry, with the continuous growing business in CDMO service; it results in gradually insufficiency of production scale. Zhubei plant's mammalian facility can accommodate two production lines and uses the most advanced 2000 liter-scale single-use bioreactor technology for upstream process, which is going to install four 2000-liter sacle single-use bioreactors in the first production line in the first stage. The downstream process uses traditional and single-use technologies for efficiency and flexibility, and its processing scale can reach 2 to 16 kg for each product batch. Each production line of Zhubei plant's mammalian facility can maximally to build up six 2000-liter sacle single-use bioreactors; It is estimated that maximum production capacity is more than 1,000 kg per year.

The construction plan can support Eirgenix's biologics development and support the growing CDMO business according to the market. In addition, Eirgenix provides CDMO service to not only domestic clients, but also international ones such as clients in the United States, Europe, Japan, etc. Eirgenix's business will continuously grow with the operation of Zhubei plant.